Reata Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (?FDA?) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich?s ataxia. The Fast Track program is designed to accelerate the development and review of products such as omaveloxolone, which are intended to treat serious diseases and for which there is an unmet medical need. Fast Track Designation enables more frequent communication with the FDA and eligibility for FDA programs such as priority review and rolling review, if relevant criteria are met.